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Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor is a secretory glycoprotein belonging to the tumor necrosis factor receptor super-family, which has been identified by 2 independent researchers 1, 2) . OPG works as an intrinsic inhibitor (decoy receptor) of the receptor activator of the nuclear factor-kb ligand (RANKL) to bind its membrane-bound receptor RANK. The RANKL/RANK/OPG pathway is associated with bone-formation and resorption, and it thus plays a role in the pathogenesis of a series of bone diseases, such as rheumatoid arthritis and osteoporosis. Mice genetically lacking the OPG gene have been reported to display osteoporosis at an early stage of life, while also demonstrating vascular calcification 3) . OPG expression is distributed in various organs associated with the bone metabolism, such as the thyroid, kidney and intestines 4) , but more interestingly, it is strongly expressed in the vasculature. The serum OPG level is reported to increase according to the severity of the atherosclerotic coronary arteries 5) , and the OPG level can also predict the prognosis of patients after acute myocardial infarction with heart failure 6) . In the present issue of Journal of atherosclerosis and thrombosis, studies by Lee and co-workers 7) , the serum OPG level was suggested to be a useful biomarker for reflecting the degree of aortic stiffness. This manuscript may thus support the hypothesis that the biological action of OPG connects to both osteoporosis and atherosclerosis, presumably through vascular calcification. However, there are several concerns that need to be addressed in future studies. First, it remains unclear whether the relationship between an increased serum OPG level and vascular stiffness is compensatory, causal, or merely an interesting association. Does OPG regulate the stiffness of the aorta by inhibiting the RANKL activity ? The authors did not measure the RANKL activity in their study, but Vik and co-workers 8) reported a limited utility of the soluble form RANKL for predicting a progression of atherosclerosis. Secondly, they did not discuss the origin of the circulating OPG levels in this study. Do the bones produce RANKL and OPG in response to atherosclerosis ? Alternatively, does the vascular wall itself contribute to the circulating OPG level ? In supporting the latter hypothesis, Koyama and co-workers 9) reported that OPG was secreted into the coronary circulation in humans. Third, they did not assess the relationship between the OPG concentration and the cardio ankle-vascular index in the healthy group, because the OPG level did not differ between the healthy and atherosclerosis groups. If they did not find any association in the healthy group, then OPG may be present in the circulation due to some other factor(s). Lastly, they did not discuss the temporal change in the OPG level following treatments, such as with statin or angiotensin type 1 receptor blocker, which potentially can cause a reduction in atherosclerosis (aortic stiffness). Specifically, it is important to elucidate the potential existence of cross-talk between OPG and the renin-angiotensin system 9) . One study demonstrated that one year of treatment with calcium channel antagonist and angiotensin type 1 receptor blocker effectively decreased the degree of aortic stiffness, and accordingly reduced the serum OPG level in hypertensive subjects 10) . Table 1 summarizes that OPG is suggested to exert a variety of unique biological actions beyond calcification, in the RANKL-dependent or -independent pathway in the vasculature. In conclusion, the proportion of elderly individuals is rising rapidly, and osteoporosis and atherosclerosis-related disorders have become increasingly important public health problems. Therefore, this study provides important information which can help to clarify the notion that OPG may play a role in the evolution of atherosclerosis and osteoporosis in the elderly population. 
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